Solana Co 8-K

What Happened
Solana Company announced on April 13, 2026 (via an 8-K) that Antonella Favit‑Van Pelt, MD, PhD, and the company mutually agreed she would separate and resign as Chief Medical Officer effective April 8, 2026. The company and Dr. Favit‑Van Pelt executed a separation agreement memorializing the terms.

Key Details

• Dr. Antonella Favit‑Van Pelt resigned as CMO effective April 8, 2026.
• Separation payment of $875,000 to be paid in a single lump sum (less applicable withholdings) within ten business days after the effective date.
• In exchange for the payment, Dr. Favit‑Van Pelt waived and released any claims related to her employment and separation.
• She remains bound by confidentiality and invention assignment provisions from her employment agreement. The separation agreement is filed as Exhibit 10.1 to the Form 8-K.

Why It Matters
This is a material C-suite departure disclosed under Item 5.02 of Form 8‑K. Investors should note the immediate cash outflow of $875,000 tied to the separation and that the company has documented a release of claims, which may reduce legal exposure related to the departure. The filing alerts shareholders to a change in medical leadership; any operational or clinical impacts would depend on the company’s succession plans (not detailed in the 8‑K).